Nkarta (NKTX)
(Delayed Data from NSDQ)
$3.89 USD
+0.18 (4.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.88 -0.01 (-0.26%) 7:12 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.89 USD
+0.18 (4.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.88 -0.01 (-0.26%) 7:12 PM ET
2-Buy of 5 2
B Value D Growth B Momentum B VGM
Zacks News
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
by Zacks Equity Research
Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
by Zacks Equity Research
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
by Zacks Equity Research
Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Should You Buy Nkarta (NKTX) Ahead of Earnings?
by Zacks Equity Research
Nkarta (NKTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Nkarta, Inc. (NKTX) a New Buy Stock
by Zacks Equity Research
Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
by Zacks Equity Research
Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Creative Medical (CELZ) Up 82% on Stem Cell Treatment Data
by Zacks Equity Research
Creative Medical Technology (CELZ) reports positive follow-up data from a pilot study evaluating StemSpine, a patented stem cell treatment for chronic lower back pain.
Wall Street Analysts See a 478% Upside in Nkarta, Inc. (NKTX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 478.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.